Moolec Science SA Ordinary Shares (MLEC)vsModerna Inc (MRNA)
MLEC
Moolec Science SA Ordinary Shares
$1.51
+2.72%
HEALTHCARE · Cap: $1.25M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 28344% more annual revenue ($2.23B vs $7.83M). MLEC leads profitability with a 0.0% profit margin vs -141.4%. MLEC earns a higher WallStSmart Score of 36/100 (F).
MLEC
Hold36
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MLEC.
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 948.0% year-over-year
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MLEC
The strongest argument for MLEC centers on Revenue Growth, Price/Book. Revenue growth of 948.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MLEC
The primary concerns for MLEC are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 7.21 is elevated, increasing financial risk.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MLEC profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.09 — expect wider price swings.
MLEC is growing revenue faster at 948.0% — sustainability is the question.
MLEC generates stronger free cash flow (-30M), providing more financial flexibility.
Bottom Line
MLEC scores higher overall (36/100 vs 21/100) and 948.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moolec Science SA Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company is headquartered in Luxembourg.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?